אלפבריו - Elfabrio

× ×ª×× × ×ª×¨××¤×

××¡× ×××¨××××ª

×××¨×©×

×§×××¦× ×¤×¨××§××××××ª (ATC4)

A16AB
Enzymes

××¨××× ×¤×¢×× (ATC5)

Pegunigalsidase alfa 2 MG / 1 ML âA16AB20

×¦××¨×ª ××ª×

×ª××-××¨××× - I.V

×¦××¨×ª ××× ××

×ª×¨××× ×××× ×ª ×ª×××¡× ×××× ×¤××××, CONCENTRATE FOR SOLUTION FOR INFUSION
××× ××¢×ª ××× ×× ××ª×¨ ×× ××¨×¢×× ××© ××××× ××ª ××ª×¨××¤× ×××ª×× ×××× ×× ××××××¥ ××¤× ×©×××¤××¢ ××¢××× ××¦×¨××

××ª××××

Elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).

× ×ª×× × ××¡×

×ª××¨×× ××××× ××¡×

19/02/2025

××××××ª ××¡×

×ª×¨××¤× ××××××ª ××¨××©×× ×¢'× ×¨××¤× ××××× ×× ××××× ×××¨×ª

××ª×××× ××¡×

××ª××××	×ª××¨×× ×××××	×ª××× ×§××× ×	Class Effect	××¦× ××××	××¡××¡ ××××××ª
××ª×¨××¤× ×ª×× ×ª× ××××¤×× ×× ××××× ××××¤× ××¨×× ×××× ×××××× ×××××¨×× ×¢× ×××× × ××××©×¨×ª ×©× ××××ª ×¤××¨× (××¡×¨ ××× ××× alpha galactosidase)	17/03/2024	×××××ª ××××××××ª	PEGUNIGALSIDASE ALFA, AGALSIDASE ALFA, AGALSIDASE BETA	××××ª ×¤××¨×, Fabry's disease, Alpha galactosidase deficiency

××¡××¨×ª ××××× ××¡×

××ª×¨××¤× ×ª×× ×ª× ××××¤×× ×× ××××× ××××¤× ××¨×× ×××× ×××××× ×××××¨×× ×¢× ×××× × ××××©×¨×ª ×©× ××××ª ×¤××¨× (××¡×¨ ××× ××× alpha galactosidase)

×¢××× ××¨××¤× ×××××¨××ª ××¢×××

××××¨×ª ××××¢ ××××××ª× ××¦×××ª ××¨×¤××× ×× ××××ª 02.12.2024

×¢××× ××¦×¨××	Â

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
×××¤××¨×× ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	××××¨×× ×-PubMed
××××¢ ××¨×©×ª	RxList WebMD Drugs.com
×©× ××¦×¨×	CHIESI FARMACEUTICI S.P.A, ITALY
×©× ××¢× ××¨××©××	MEGAPHARM LTD
×¨××©×××	×ª××¨×× ×××©×: 6/2023. ×¨××©××× ××ª××¨××:
×ª××¨×× ×¢×××× ×××¨××	19/05/2025

השינוי האחרון נעשה בֹ־19 במאי 2025 ב־03:43

אלפבריו - Elfabrio

ויקיתרופות